Lee Schwartzberg, MD, FACP | Authors

August 22, 2021

This special episode of “Oncology Peer Review On-The-Go” features Lee Schwartzberg, MD, FACP discussing treatment patterns in HR-positive breast cancer with.

July 12, 2021

Dr. Lee Schwartzberg comments on unmet needs in the treatment of early-stage HR+ [hormone receptor-positive] breast cancer.

July 12, 2021

Current recommendations for conducting genomic testing in patients with HR+ [hormone receptor-positive] breast cancer, as outlined by the NCCN clinical practice guidelines.

July 12, 2021

Dr. Lee Schwartzberg highlights recent changes to the NCCN guidelines in terms of guidance for genomic testing in HR-positive breast cancer based on updates to the RxPONDER trial and data supporting the use of the Breast Cancer Index.

July 07, 2021

Common scenarios for which genomic testing is recommended to aid in treatment decisions for patients with hormone receptor-positive breast cancer.

July 07, 2021

Lee Schwartzberg, MD, FACP, of West Cancer Center & Research Institute, discusses the role of genomic testing in hormone receptor-positive breast cancer and compares information provided by various assays approved for use.

June 28, 2021

An overview of predictive and prognostic biomarkers used by breast oncologists to aid in adjuvant treatment decisions for HR-positive disease, as outlined by the NCCN guidelines.

June 28, 2021

The rationale for treating patients with early stage HR-positive breast cancer with extended adjuvant therapy based on lessons learned through clinical trial evidence and real-world practice.